Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib maintenance after intensive immunochemotherapy and autologous transplant for mantle cell lymphoma
NL-OMON24708Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Mar 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in mantle cell lymphoma (MCL) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Mar 2007; status: recruiting.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON24708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24708.